Novartis pulls rival to Roche’s risdiplam in SMA, says market limited

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Dec 6, 2019 at 9:52 AM.

  1. #1 cafead, Dec 6, 2019 at 9:52 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,979
    Likes Received:
    3
    via While Roche’s oral risdiplam has been tipped by some analysts to be a big contender in the market for spinal muscular atrophy (SMA) treatments, Novartis’ research chief Jay Bradner has a different take.

    article source
     
    Quote

Reply to Thread